DBV Technologies Launches THRIVE Trial of VIASKIN Peanut Patch in Infants
DBV Technologies launches THRIVE trial of VIASKIN Peanut Patch in infants ages 6–12 months with confirmed peanut allergy, targeting...
Ziftomenib Plus Venetoclax/Azacitidine Shows Strong Response in R/R NPM1-Mutated AML
Ziftomenib plus venetoclax/azacitidine achieved 70% composite complete remission in venetoclax-naïve R/R NPM1-mutated AML patients, with rapid response and mana
Obexelimab Meets Primary Endpoint in Phase 3 IgG4-RD Trial
Obexelimab Phase 3 IgG4-RD trial hits primary endpoint with 56% flare reduction and significant steroid-sparing benefits in largest study...
Nipocalimab Shows 58% Response Rate in Autoantibody-Positive SLE Patients
Nipocalimab shows 58% response rate in autoantibody-positive SLE patients in Phase 2 JASMINE trial, with sustained benefit at Week...
Apalutamide Cuts Metastasis Risk 20% in Prostate Cancer Surgery Trial
Apalutamide reduced metastasis risk by 20% in the Phase 3 PROTEUS trial of prostate cancer surgery patients with high-risk...
FDA Accepts NDA for Roche’s Giredestrant in Early-Stage Breast Cancer
FDA accepts Roche's giredestrant NDA for early-stage breast cancer with 30% reduction in recurrence or death in phase III...
When AI Picks Your Site, Execution Still Happens in the Building
ASCO and Ryght AI are using machine learning to select breast cancer trial sites. Here's what that means for...
The Trial Architecture Neurodegenerative Disease Has Always Needed — And Kept Refusing to Build
MAMS platform trials could end neurology's 99.6% drug failure rate. The Lancet just made the case. Here's what the...
Psychedelic Trials Are Effectively Open-Label. The FDA Has to Decide What to Do With That.
A meta-analysis of 112 psychedelic RCTs found >90% unblinding rates, meaning every efficacy estimate in the field may be...
Decentralized Trials Are Everywhere. Nobody Agrees What They’re For.
DCTs promise faster enrollment and broader diversity, but sponsors, CROs, sites, and regulators each want something different—and the TELEPIK...